scholarly journals Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

2015 ◽  
Vol 51 (2) ◽  
pp. 137-145 ◽  
Author(s):  
J. Spicer ◽  
R. Baird ◽  
A. Suder ◽  
N. Cresti ◽  
J. Garcia Corbacho ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Phase 1 ◽  
Solid Tumours ◽  
Dose Escalation Study

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

2009 ◽  
Vol 45 (13) ◽  
pp. 2333-2341 ◽  
Author(s):  
J.C. Soria ◽  
C. Massard ◽  
N. Magné ◽  
Th. Bader ◽  
C.D. Mansfield ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Phase 1 ◽  
Dose Escalation Study

Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 2540-2540 ◽  
Author(s):  
D. S. Hong ◽  
B. S. Koetz ◽  
R. Kurzrock ◽  
N. N. Senzer ◽  
W. Hanekom ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Dose Escalation Study

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

2012 ◽  
Vol 48 (2) ◽  
pp. 179-186 ◽  
Author(s):  
Patrick Schöffski ◽  
Ahmad Awada ◽  
Herlinde Dumez ◽  
Thierry Gil ◽  
Sylvie Bartholomeus ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Solid Tumours ◽  
The Novel ◽  
Dose Escalation Study
Sign in / Sign up

Export Citation Format

Share Document